Past-Year Use Prevalence of Cannabidiol, Cannabigerol, Cannabinol, and Δ8-Tetrahydrocannabinol Among US Adults

Adrianne R Wilson-Poe; Tristin Smith; Michael R Elliott; Daniel J Kruger; Kevin F Boehnke

doi:10.1001/jamanetworkopen.2023.47373

Past-Year Use Prevalence of Cannabidiol, Cannabigerol, Cannabinol, and Δ8-Tetrahydrocannabinol Among US Adults

JAMA Netw Open. 2023 Dec 1;6(12):e2347373. doi: 10.1001/jamanetworkopen.2023.47373.

Authors

Adrianne R Wilson-Poe¹, Tristin Smith², Michael R Elliott³, Daniel J Kruger^{4

5}, Kevin F Boehnke²

Affiliations

¹ Dow Neurobiology, Legacy Research Institute, Legacy Health, Portland, Oregon.
² Chronic Pain and Fatigue Research Center, Anesthesiology Department, University of Michigan Medical School, Ann Arbor.
³ Biostatistics Department, University of Michigan School of Public Health, Ann Arbor.
⁴ Department of Community Health and Health Behavior, University at Buffalo, Buffalo, New York.
⁵ Jacobs School of Medicine and Biomedical Sciences, University at Buffalo, Buffalo, New York.

No abstract available

Plain language summary

This survey study characterizes past-year use prevalence and factors associated with use of cannabidiol, cannabigerol, cannabinol, and Δ8-tetrahydrocannabinol among US adults.

Publication types

Research Support, Non-U.S. Gov't
Research Support, N.I.H., Extramural

MeSH terms

Adult
Cannabidiol*
Cannabinol*
Dronabinol
Humans
Prevalence

Substances

cannabigerol
Cannabinol
Dronabinol
Cannabidiol

Grants and funding

K01 DA049219/DA/NIDA NIH HHS/United States